<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Surgery and Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Surgery and Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Хирургия и онкология</trans-title></trans-title-group></journal-title-group><issn publication-format="electronic">2949-5857</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">687</article-id><article-id pub-id-type="doi">10.17650/2949-5857-2024-14-1-21-31</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>LITERATURE REVIEW</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОР ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Changes in clinical guidelines for the treatment of colorectal cancer in 2024</article-title><trans-title-group xml:lang="ru"><trans-title>Изменения в клинических рекомендациях по лечению колоректального рака в 2024 году</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9303-8379</contrib-id><name-alternatives><name xml:lang="en"><surname>Gordeev</surname><given-names>S. S.</given-names></name><name xml:lang="ru"><surname>Гордеев</surname><given-names>С. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Sergey Sergeevich Gordeev</p><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>Сергей Сергеевич Гордеев</p><p>115522 Москва, Каширское шоссе, 24</p></bio><email>ss.netoncology@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5615-7806</contrib-id><name-alternatives><name xml:lang="en"><surname>Fedyanin</surname><given-names>M. Yu.</given-names></name><name xml:lang="ru"><surname>Федянин</surname><given-names>М. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p><p>8 Sosenskiy Stan St., Moscow 108801</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p><p>108801 п. Коммунарка, ул. Сосенский стан, 8</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4944-4035</contrib-id><name-alternatives><name xml:lang="en"><surname>Chernykh</surname><given-names>M. V.</given-names></name><name xml:lang="ru"><surname>Черных</surname><given-names>М. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3919-9067</contrib-id><name-alternatives><name xml:lang="en"><surname>Rubakov</surname><given-names>Ye. G.</given-names></name><name xml:lang="ru"><surname>Рыбаков</surname><given-names>Е. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>2 Salyama Adilya St., Moscow 123423</p></bio><bio xml:lang="ru"><p>123423 Москва, ул. Саляма Адиля, 2</p></bio><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6641-7229</contrib-id><name-alternatives><name xml:lang="en"><surname>Karachun</surname><given-names>A. M.</given-names></name><name xml:lang="ru"><surname>Карачун</surname><given-names>А. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758</p></bio><bio xml:lang="ru"><p>197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68</p></bio><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5961-2958</contrib-id><name-alternatives><name xml:lang="en"><surname>Nevolskikh</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Невольских</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>4 Koroleva St., Obninsk 249036</p></bio><bio xml:lang="ru"><p>249036 Обнинск, ул. Королева, 4</p></bio><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2245-214X</contrib-id><name-alternatives><name xml:lang="en"><surname>Tryakin</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Трякин</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9289-1247</contrib-id><name-alternatives><name xml:lang="en"><surname>Mamedli</surname><given-names>Z. Z.</given-names></name><name xml:lang="ru"><surname>Мамедли</surname><given-names>З. З.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Moscow Multidisciplinary Clinical Center “Kommunarka”, Moscow Healthcare Department</institution></aff><aff><institution xml:lang="ru">БУЗ «Московский многопрофильный клинический центр «Коммунарка» Департамента здравоохранения г. Москвы»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">A.N. Ryzhikh National Medical Research Center of Coloproctology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр колопроктологии им. А. Н. Рыжих» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Петрова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">A. F. Tsyb Medical Radiological Research Center – a branch of the National Medical Research Radiology Center, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">Медицинский радиологический научный центр им. А. Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-05-02" publication-format="electronic"><day>02</day><month>05</month><year>2024</year></pub-date><volume>14</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>21</fpage><lpage>31</lpage><history><date date-type="received" iso-8601-date="2024-04-30"><day>30</day><month>04</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-04-30"><day>30</day><month>04</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, ABV-press</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, АБВ-пресс</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">ABV-press</copyright-holder><copyright-holder xml:lang="ru">АБВ-пресс</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://onco-surgery.info/jour/about/editorialPolicies</ali:license_ref></license></permissions><self-uri xlink:href="https://onco-surgery.info/jour/article/view/687">https://onco-surgery.info/jour/article/view/687</self-uri><abstract xml:lang="en"><p><bold>Aim.</bold> The ensuring that changes to clinical guidelines can be discussed more widely before they are formally introduced into clinical practice.</p><p><bold>Materials and methods.</bold> A brief review of the literature and rationale for each proposed major change in the treatment section is presented. The refusal to carry out preoperative radiation therapy for cancer of the upper ampullary rectum, the narrowing of indications for preoperative radiation therapy for cancer of the mid-ampullary rectum, as well as the expansion of indications for total non-adjuvant chemotherapy for rectal cancer with damage to the circular resection margin are discussed. Changes to the drug treatment section are discussed.</p><p><bold>Results.</bold> This article presents planned changes to clinical guidelines for the treatment of non-metastatic colorectal cancer in 2024. The most significant alterations concerned neoadjuvant treatment of rectal cancer and adjuvant treatment of colon cancer. A new algorithm was proposed for choosing rectal cancer neoadjuvant therapy, considering individual treatment decisions.</p><p><bold>Conclusion.</bold> A consensus was achieved concerning the necessity to expand indications for neoadjuvant rectal cancer chemotherapy, but only in patients with good functional status. The most benefit can be achieved in patients, for whom complete clinical response is the aim of the treatment and in patients with positive circumferential resection margin.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель исследования</bold> – обеспечение возможности более широкого обсуждения изменений в клинических рекомендациях до их официального внедрения в клиническую практику.</p><p><bold>Материалы и методы.</bold> Представлены краткий обзор литературы и обоснование каждого предлагаемого крупного изменения в разделе лечения. Обсуждается отказ от проведения предоперационной лучевой терапии при раке верхнеампулярного отдела прямой кишки, сужение показаний к предоперационной лучевой терапии при раке среднеампулярного отдела прямой кишки, а также расширение показаний к проведению тотальной неаоадъювантной химиотерапии при раке прямой кишки с поражением циркулярной границы резекции. Обсуждаются изменения в разделе лекарственного лечения.</p><p><bold>Результаты.</bold> В данной статье представлены планируемые изменения клинических рекомендаций по лечению неметастатического рака ободочной и прямой кишки в 2024 году. Ключевые изменения коснулись предоперационного лечения рака прямой кишки, предложен ряд изменений в разделе адъювантного лечения рака ободочной кишки. Предложен новый алгоритм выбора метода предоперационного лечения рака прямой кишки с учетом индивидуальных особенностей пациента.</p><p><bold>Выводы.</bold> Достигнут консенсус о необходимости расширения показаний к проведению неоадъювантной химиотерапии, однако только у пациентов с высоким функциональным статусом. Наибольшее преимущество могут получить пациенты, когда целью лечения является достижение полного клинического ответа на лечение, и пациенты с исходным поражением циркулярной границы резекции.</p></trans-abstract><kwd-group xml:lang="en"><kwd>rectal cancer</kwd><kwd>colon cancer</kwd><kwd>colorectal cancer</kwd><kwd>clinical guidelines</kwd><kwd>neoadjuvant chemotherapy</kwd><kwd>total neoadjuvant therapy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак прямой кишки</kwd><kwd>рак ободочной кишки</kwd><kwd>колоректальный рак</kwd><kwd>клинические рекомендации</kwd><kwd>неоадъювантная химиотерапия</kwd><kwd>тотальная неоадъювантная терапия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Sakamoto T., Shimura M., Kitano S. et al. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology 2007;243(1):132–9. DOI: 10.1148/radiol.2431051825</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Engstrom P.F., Arnoletti J.P., Benson A.B. 3rd et al. Rectal cancer. J Natl Compr Canc Netw 2009:7(8):838–81. DOI: 10.6004/jnccn.2009.0057</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>De Caluwé L., Van Nieuwenhove Y., Ceelen W.P. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2013(2):CD006041. DOI: 10.1002/14651858.CD006041.pub3</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Bahadoer R.R., Dijkstra E.A., van Etten B. et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021;22(1):29–42. DOI: 10.1016/S1470-2045(20)30555-6</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Dijkstra E.A., Nilsson P.J., Hospers G.A.P. et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery–a five-year follow-up of the RAPIDO trial. Ann Surg 2023;278(4):e766–72. DOI: 10.1097/SLA.0000000000005799</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Song J.H., Jeong J.U., Lee J.H. et al. Preoperative chemoradiotherapy versus postoperative chemoradiotherapy for stage II–III resectable rectal cancer: a meta-analysis of randomized controlled trials. Radiat Oncol J 2017;35(3): 198–207. DOI: 10.3857/roj.2017.00059</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Battersby N.J., How P., Moran B. et al. Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY II study. Ann Surg 2016;263(4):751–60. DOI: 10.1097/SLA.0000000000001193</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Marinello F.G., Frasson M., Baguena G. et al. Selective approach for upper rectal cancer treatment: total mesorectal excision and preoperative chemoradiation are seldom necessary. Dis Colon Rectum 2015;58(6):556–65. DOI: 10.1097/DCR.0000000000000349</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Rosenberg R., Maak M., Schuster T. et al. Does a rectal cancer of the upper third behave more like a colon or a rectal cancer? Dis Colon Rectum 2010;53(5):761–70. DOI: 10.1007/DCR.0b013e3181cdb25a</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Folkesson J., Birgisson H., Pahlman L. et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005;23(24):5644–50. DOI: 10.1200/JCO.2005.08.144</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Sebag-Montefiore D., Stephens R.J., Steele R. et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009;373(9666):811–20. DOI: 10.1016/S0140-6736(09)60484-0</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Van Gijn W., Marijnen C.A., Nagtegaal I.D. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011;12(6):575–82. DOI: 10.1016/S1470-2045(11)70097-3</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Morton D., Seymour M., Magill L. et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol 2023;41(8):1541. DOI: 10.1200/JCO.22.00046</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Hu H., Huang M., Li Y. et al. Perioperative chemotherapy with mFOLFOX6 or CAPOX for patients with locally advanced colon cancer (OPTICAL): A multicenter, randomized, phase 3 trial. J Clin Oncol 2022;40(16_suppl). DOI: 10.1200/JCO.2022.40.16_suppl.3500</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Jensen L.H., Kjaer M.L., Holländer N.H., Larsen F.O. Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial. J Clin Oncol 2023;41(17_suppl):LBA3503. DOI: 10.1200/JCO.2023.41.17_suppl.LBA3503</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Karoui M., Rullier A., Piessen G. et al. Perioperative FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a phase II multicenter randomized controlled trial (PRODIGE 22). Ann Surg 2020;271(4):637–45. DOI: 10.1097/SLA.0000000000003454</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Ngan S.Y., Burmeister B., Fisher R.J. et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012;30(31):3827–33. DOI: 10.1200/JCO.2012.42.9597</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Cisel B., Pietrzak L., Michalski W. et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol 2019;30(8):1298–303. DOI: 10.1093/annonc/mdz186</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Dijkstra E.A., Hospers G.A.P., Kranenbarg E.M. et al. Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer – The RAPIDO trial. Radiother Oncol 2022;171:69–76. DOI: 10.1016/j.radonc.2022.04.013</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Birgisson H., Påhlman L., Gunnarsson U., Glimelius B. Late adverse effects of radiation therapy for rectal cancer – a systematic overview. Acta Oncol 2007;46(4):504–16. DOI: 10.1080/02841860701348670</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Grothey A., Sobrero A.F., Shields A.F. et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018;378(13):1177–88. DOI: 10.1056/NEJMoa1713709</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Schrag D. PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC)(Alliance N1048). American Society of Clinical Oncology 2023.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Mei W.-J., Wang X.Z., Li Y.F. et al. Neoadjuvant chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): initial results of a phase III trial. Ann Surg 2023;277(4):557–64. DOI: 10.1097/SLA.0000000000005780</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Hazen S.-M.J., Sluckin T.C., Intven M.P.W. et al. Abandonment of Routine Radiotherapy for Nonlocally Advanced Rectal Cancer and Oncological Outcomes. JAMA Oncol 2024;10(2):202–11. DOI: 10.1001/jamaoncol.2023.5444</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Sychev S., Ponomarenko A., Chernyshov S. et al. Total neoadjuvant therapy in rectal cancer: a network meta-analysis of randomized trials. Ann Coloproctol 2023;39(4):289–300. DOI: 10.3393/ac.2022.00920.0131</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Verheij F.S., Omer D.M., Williams H. et al. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. J Clin Oncol 2023:42(5):500–6. DOI: 10.1200/JCO.23.01208</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Liao C.-K., Kuo Y.T., Lin Y.C. et al. Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer: a systematic review and meta-analysis. Curr Oncol 2022;29(5):3708–27. DOI: 10.3390/curroncol29050297</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Verheij F.S., Omer D.M.R., Williams H. et al. Sustained organ preservation in patients with rectal cancer treated with total neoadjuvant therapy: Long-term results of the OPRA trial. J Clin Oncol 2023;41(16_suppl). DOI: 10.1200/JCO.2023.41.16_suppl.352</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Romesser P.B., Park B.K., Nemirovsky D. et al. Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long-course chemoradiation versus short-course radiation therapy. J Clin Oncol 2023;41(4_suppl). DOI: 10.1200/JCO.2023.41.4_suppl.10</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Van der Valk M.J., Hilling D.E., Bastiaannet E. et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch &amp; Wait Database (IWWD): an international multicentre registry study. Lancet 2018;391(10139):2537–45. DOI: 10.1016/S0140-6736(18)31078-X</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Ellis C.T., Cole A.L., Sanoff H.K. et al. Evaluating surveillance patterns after Chemoradiation-only compared with conventional Management for Older Patients with rectal cancer. J Am Coll Surg 2019;228(5):782–91. DOI: 10.1016/j.jamcollsurg.2019.01.010</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Giordano P., Efron J., Vernava A.M. 3rd et al. Strategies of followup for colorectal cancer: a survey of the American Society of Colon and Rectal Surgeons. Tech Coloproctol 2006;10(3):199–207. DOI: 10.1007/s10151-006-0280-3</mixed-citation></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">Fedyanin M., Glakov O., Gordeev S. et al. Cancer of the colon, rectosigmoid junction and rectum. Zlokachestvennye opukholi = Malignant tumours 2023;13(3s2-1):425–82. (In Russ.). DOI: 10.18027/2224-5057-2023-13-3s2-1-425-482</mixed-citation><mixed-citation xml:lang="ru">Федянин М., Гладков О., Гордеев С. и др. Рак ободочной кишки, ректосигмоидного соединения и прямой кишки. Злокачественные опухоли 2023;13(3s2-1):425–82. DOI: 10.18027/2224-5057-2023-13-3s2-1-425-482</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">Fedyanin M., Tryakin A.A., Bulanov A.A. et al. On the question of the number of lymph nodes required for study in stage II colon cancer. Onkologicheskaya Koloproktologiya = Colorectal Oncology 2019;9(1):42–50. (In Russ.). DOI: 10.17650/2220-3478-2019-9-1-42-50</mixed-citation><mixed-citation xml:lang="ru">Федянин М., Трякин А.А., Буланов А.А. и др. К вопросу о числе лимфатических узлов, необходимых к изучению при раке толстой кишки II стадии. Тазовая хирургия и онкология 2019;9(1):42–50. DOI: 10.17650/2220-3478-2019-9-1-42-50</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><mixed-citation>Jeon J., Shen L., Kim Y. et al. The number of lymph nodes examined as a poor prognosis factor in stage II and stage III colon cancer patients undergoing curative surgery. J Clin Oncol 2023;41(16_suppl). DOI: 10.1200/JCO.2023.41.16_suppl.3612</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Ahmed F., Selfridge J., Kakishet H. et al. SO-19 The outcome of resected stage II colon cancer patients with deficient mismatch repair T4 tumors: A National Cancer Database analysis. Ann Oncol 2023;34(1_suppl):S170. DOI: 10.1016/j.annonc.2023.04.491</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Fleming P., Chen Ch., Moore D.F. et al. High-risk MSI-H stage II colon cancer: Treatment patterns and outcomes. J Clin Oncol 2022;40(16_suppl). DOI: 10.1200/JCO.2022.40.16_suppl.e15588</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Oki E., Kotani D., Nakamura Y. et al. Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: Updated results from GALAXY study in the CIRCULATE-Japan. J Clin Oncol 2023;41(16_suppl). DOI: 10.1200/JCO.2023.41.16_suppl.3521</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Tie J., Cohen J.D., Lahouel K. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med 2022;386(24):2261–72. DOI: 10.1056/NEJMoa2200075</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Cohen S.A., Kasi P.M., Aushev V.N., Hanna D. Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I–III colorectal cancer. J Clin Oncol 2023;41(4_suppl):5. DOI: 10.1200/JCO.2023.41.4_suppl.5</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Karoui M., Gallois C., Piessen G. et al. Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years’ follow-up results of the PRODIGE 22 phase II randomized multicentre trial. Colorectal Dis 2021;23(6):1357–69. DOI: 10.1111/codi.15585</mixed-citation></ref></ref-list></back></article>
